PMID- 35483235 OWN - NLM STAT- MEDLINE DCOM- 20220621 LR - 20231105 IS - 1878-1705 (Electronic) IS - 1567-5769 (Linking) VI - 109 DP - 2022 Aug TI - Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. PG - 108786 LID - S1567-5769(22)00270-3 [pii] LID - 10.1016/j.intimp.2022.108786 [doi] AB - In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, causing a global pandemic called COVID-19. Currently, there is no definitive treatment for this emerging disease. Global efforts resulted in developing multiple platforms of COVID-19 vaccines, but their efficacy in humans should be wholly investigated in the long-term clinical and epidemiological follow-ups. Despite the international efforts, COVID-19 vaccination accompanies challenges, including financial and political obstacles, serious adverse effects (AEs), the impossibility of using vaccines in certain groups of people in the community, and viral evasion due to emerging novel variants of SARS-CoV-2 in many countries. For these reasons, passive immunotherapy has been considered a complementary remedy and a promising way to manage COVID-19. These approaches arebased on reduced inflammation due to inhibiting cytokine storm phenomena, immunomodulation,preventing acute respiratory distress syndrome (ARDS), viral neutralization, anddecreased viral load. This article highlights passive immunotherapy and immunomodulation approaches in managing and treating COVID-19 patients and discusses relevant clinical trials (CTs). CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Farhangnia, Pooya AU - Farhangnia P AD - Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States. FAU - Dehrouyeh, Shiva AU - Dehrouyeh S AD - Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States. FAU - Safdarian, Amir Reza AU - Safdarian AR AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Department of Pathology, School of Medicine, Alborz University of Medical Sciences, Alborz, Iran. FAU - Farahani, Soheila Vasheghani AU - Farahani SV AD - Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. FAU - Gorgani, Melika AU - Gorgani M AD - Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States. FAU - Rezaei, Nima AU - Rezaei N AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. FAU - Akbarpour, Mahzad AU - Akbarpour M AD - Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Chicago, United States; Advanced Cellular Therapeutics Facility (ACTF), Hematopoietic Cellular Therapy Program, Section of Hematology & Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, United States. Electronic address: Makbarpour@medicine.bsd.uchicago.edu. FAU - Delbandi, Ali-Akbar AU - Delbandi AA AD - Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Delbandi.ak@iums.ac.ir. LA - eng PT - Journal Article PT - Review DEP - 20220421 PL - Netherlands TA - Int Immunopharmacol JT - International immunopharmacology JID - 100965259 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/therapy MH - COVID-19 Vaccines MH - Humans MH - Immunization, Passive/adverse effects MH - Pandemics MH - SARS-CoV-2 PMC - PMC9021130 OTO - NOTNLM OT - Acute Respiratory Disease Syndrome OT - COVID-19 OT - Cellular Immunotherapy OT - Convalescent Plasma (CP) Therapy OT - Immunomodulation OT - Monoclonal Antibody OT - Passive Immunotherapy OT - SARS-CoV-2 EDAT- 2022/04/29 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/04/28 18:20 PHST- 2022/01/23 00:00 [received] PHST- 2022/04/14 00:00 [revised] PHST- 2022/04/16 00:00 [accepted] PHST- 2022/04/29 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/04/28 18:20 [entrez] AID - S1567-5769(22)00270-3 [pii] AID - 10.1016/j.intimp.2022.108786 [doi] PST - ppublish SO - Int Immunopharmacol. 2022 Aug;109:108786. doi: 10.1016/j.intimp.2022.108786. Epub 2022 Apr 21.